Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ramlift
- Development stage
- Phase 4
- Lead developer
- Lyceum
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Ramlift is a branded generic fixed-dose combination of donepezil (an acetylcholinesterase inhibitor) and memantine (an N-methyl-D-aspartate [NMDA] receptor antagonist) developed by Lyceum Life Sciences. It is indicated for the treatment of moderate to severe dementia associated with Alzheimer's disease. Donepezil works by inhibiting the acetylcholinesterase enzyme, thereby increasing the concentration of acetylcholine in the brain to improve cognitive function. Memantine acts as a non-competitive NMDA receptor antagonist, regulating glutamate activity to protect neurons from excitotoxicity. Together, these two agents provide complementary mechanisms to manage cognitive decline and improve daily functioning in patients with Alzheimer's disease.
- Brand names
- Ramlift
- Other names
- Donepezil + memantineDonepezil hydrochloride + memantine hydrochlorideMemantine + donepezil
02
Targets
HTR3A (5-hydroxytryptamine receptor 3A)AcetylcholinesteraseButyrylcholinesteraseCHRNA7 (α7 nicotinic receptor)SIGMAR1 (Sigma non-opioid intracellular receptor 1)NMDAR (Glutamate receptor ionotropic, NMDA)
Beyond the preview
Go deeper on Ramlift.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ramlift.